
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is a commercial-stage medical technology company that offers intraocular lens technology for improved vision after cataract surgery. Despite a decline in revenue and earnings in the latest quarter, management has reiterated their revenue guidance for 2026 and expects improvement in utilization and cash burn. Potential upside drivers include faster LDD installed base growth, higher utilization, and margin improvement, leading to a Buy rating from the analyst. However, risks include limited adoption, disappointing commercial execution, competition in the IOL market, and potential for dilutive financing.
Bears say
RxSight is facing a number of risks that could inhibit the company's growth, including limited product adoption due to the need for additional capital equipment, potential for increased competition in the intraocular lens market, and potential financing challenges. Despite relatively strong financials, with a 77.5% gross margin and reduced operating expenses, the company's recent revenue growth has slowed, and overall market share in the premium category remains relatively low. Finally, while the collaboration with ALC may bring in significant upfront cash and development milestones, there is uncertainty around the potential commercialization and royalty payments for this partnership.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares